Timeline

Explore Our History

Established in 2005 through the merger of Daiichi Pharmaceutical and Sankyo, Daiichi Sankyo has a rich history spanning more than 100 years.

2005

  • 2005

    Established by joint holding company of Sankyo Co., Ltd. and Daiichi Pharmaceutical Co., Ltd.

  • 2006

    Began operations of Daiichi Sankyo Healthcare Co., Ltd.; Daiichi Sankyo, Inc.; and Daiichi Sankyo Europe GmbH

  • 2006

    Launched Urief®, a drug for dysuria (Daiichi Pharmaceutical Co., Ltd.)

  • 2007

    Began operations on April 1, 2007 as Daiichi Sankyo Co., Ltd.

  • 2008

    Acquired U3 Pharma GmbH of Germany and Ranbaxy Laboratories Ltd. of India

  • 2009

    Launched Prasugrel, an antiplatelet agent and global product, in Germany (as Efient®) and the United States (as Effient®)

  • 2010

    Launched Rezaltas®, a high-affinity ARB/long-acting calcium antagonist compound

  • 2010

    Began operations of Daiichi Sankyo Espha Co., Ltd.

  • 2010

    Launched Inavir®, an anti-influenza virus agent

  • 2011

    Acquired Plexxikon Inc. of the United States

  • 2011

    Began operations of Kitasato Daiichi Sankyo Vaccine Co., Ltd.

  • 2011

    Launched Memary® for treatment of Alzheimer's disease

  • 2011

    Launched Lixiana®, an oral FXa inhibitor

  • 2011

    Launched Nexium®, a proton pump inhibitor

  • 2011

    Consolidated Japan head office and head offices of Japan Group companies into three office buildings in the Nihonbashi area of Tokyo, Japan

  • 2011

    Established wholly-owned subsidiary Daiichi Sankyo (China) Holdings Co., Ltd.

  • 2012

    Opened Daiichi Sankyo Kusuri Museum in Tokyo

  • 2012

    Launched RANMARK®, an antibody that targets RANK ligand

  • 2012

    Began operations of Japan Vaccine Co., Ltd., a joint venture with GlaxoSmithKline K.K.

  • 2012

    Launched TENELIA®, a therapeutic agent for type 2 diabetes

  • 2013

    Launched natural tetrahydrobiopterin agent Biopten® Granules 10%

  • 2014

    Launched oral antiplatelet agent Efient in Japan

  • 2014

    Launched CANAGLU® Tablets 100mg for treatment of Type 2 Diabetes Mellitus

  • 2014

    Received approval in Japan for additional AF and VTE indications for LIXIANA® (edoxaban)

  • 2014

    Acquired biopharmaceutical company Ambit Biosciences

  • 2015

    Launched edoxaban, an oral, once-daily anti-coagulant global product, in the United States (as SAVAYSA®) and in Europe (as LIXIANA®)

  • 2015

    Launched Methylene Blue Injection 50mg, a treatment for methemoglobinemia

  • 2015

    Launched MOVANTIK®, a treatment for opioid-induced constipation (OIC), in the United States via co-commercialization agreement with AstraZeneca

  • 2015

    Ranbaxy Laboratories Limited acquired by Sun Pharmaceutical Industries Ltd. via all-stock transition

  • 2015

    Daiichi Sankyo Healthcare acquired mail-order cosmetics and health food business, Im Co., Ltd.

  • 2015

    Launched Squarekids® subcutaneous injection syringe, a tetravalent combination vaccine for the prevention of diphtheria, pertussis, tetanus, and poliomyelitis (polio)

Today